Literature DB >> 22548008

Prevalence of self-reported memory problems in adult cancer survivors: a national cross-sectional study.

Pascal Jean-Pierre1, Paul C Winters, Tim A Ahles, Michael Antoni, F Daniel Armstrong, Frank Penedo, Steven E Lipshultz, Tracie L Miller, Kevin Fiscella.   

Abstract

PURPOSE: Cancer and its treatments can impair cognitive function, especially memory, leading to diminished quality of life. Prevalence studies of cancer treatment-related memory impairment have not been conducted in the adult-onset cancer population.
METHODS: To determine the prevalence of self-reported memory (SRM) problems in people with and without a history of cancer, we analyzed data from a large, nationally representative sample of the civilian, noninstitutionalized US population. Participants answered the yes-or-no question, "Are you limited in any way because of difficulty remembering or because you experience periods of confusion?" Age, sex, race/ethnicity, education, poverty, and general health were controlled.
RESULTS: The sample (N = 9,819) consisted of 4,862 men and 4,957 women age 40 years and older. There were 1,938 blacks, 5,552 whites, 1,998 Hispanics, and 331 participants categorized as other race/multiracial. Of these, 1,305 reported a history of cancer; 8,514 did not. Memory problems were self-reported more often by participants with a history of cancer (14%) than by those without (8%). Having had cancer was independently associated with SRM impairment (adjusted odds ratio, 1.4; 95% CI, 1.08 to 1.83). Other predictors of memory impairment were age, lower education, lower income, and poorer general health (P < .01 for all). Participants with cancer had a 40% greater likelihood of reporting memory problems relative to those without cancer.
CONCLUSION: Cancer history independently predicted SRM impairment. Prevalence of SRM impairment in people with a history of cancer/cancer treatment is substantial and increasing. Health care providers should assess and be ready to treat memory impairment in patients with a history of cancer.

Entities:  

Year:  2011        PMID: 22548008      PMCID: PMC3266313          DOI: 10.1200/JOP.2011.000231

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN: 1554-7477            Impact factor:   3.840


  17 in total

1.  Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma.

Authors:  Tim A Ahles; Andrew J Saykin; Charlotte T Furstenberg; Bernard Cole; Leila A Mott; Karen Skalla; Marie B Whedon; Sarah Bivens; Tara Mitchell; E Robert Greenberg; Peter M Silberfarb
Journal:  J Clin Oncol       Date:  2002-01-15       Impact factor: 44.544

2.  Cardiotoxicity after childhood cancer: beginning with the end in mind.

Authors:  Steven E Lipshultz; M Jacob Adams
Journal:  J Clin Oncol       Date:  2010-02-08       Impact factor: 44.544

3.  Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy.

Authors:  F S van Dam; S B Schagen; M J Muller; W Boogerd; E vd Wall; M E Droogleever Fortuyn; S Rodenhuis
Journal:  J Natl Cancer Inst       Date:  1998-02-04       Impact factor: 13.506

4.  Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma.

Authors:  S B Schagen; F S van Dam; M J Muller; W Boogerd; J Lindeboom; P F Bruning
Journal:  Cancer       Date:  1999-02-01       Impact factor: 6.860

5.  'Chemobrain' in breast carcinoma?: a prologue.

Authors:  Jeffrey S Wefel; Renato Lenzi; Richard Theriault; Aman U Buzdar; Scott Cruickshank; Christina A Meyers
Journal:  Cancer       Date:  2004-08-01       Impact factor: 6.860

Review 6.  Cancer survivorship: rethinking the cancer control continuum.

Authors:  Julia H Rowland
Journal:  Semin Oncol Nurs       Date:  2008-08       Impact factor: 2.315

7.  The impact of cognitive function on medication management: three studies.

Authors:  Carol S Stilley; Catherine M Bender; Jacqueline Dunbar-Jacob; Susan Sereika; Christopher M Ryan
Journal:  Health Psychol       Date:  2010-01       Impact factor: 4.267

8.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

9.  Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer.

Authors:  Nadine Tchen; Helen G Juffs; Fiona P Downie; Qi-Long Yi; Hanxian Hu; Irene Chemerynsky; Mark Clemons; Michael Crump; Paul E Goss; David Warr; Mary E Tweedale; Ian F Tannock
Journal:  J Clin Oncol       Date:  2003-11-15       Impact factor: 44.544

Review 10.  Cognitive impairment associated with chemotherapy for cancer: report of a workshop.

Authors:  Ian F Tannock; Tim A Ahles; Patricia A Ganz; Frits S Van Dam
Journal:  J Clin Oncol       Date:  2004-06-01       Impact factor: 44.544

View more
  17 in total

Review 1.  Memory and cancer: a review of the literature.

Authors:  Graham J McDougall; JoAnn S Oliver; Forrest Scogin
Journal:  Arch Psychiatr Nurs       Date:  2014-03-22       Impact factor: 2.218

2.  Trends in Memory Problems and Race/Ethnicity in the National Health and Examination Survey, 1999-2014.

Authors:  Alejandra Casillas; Li-Jung Liang; Stefanie Vassar; Arleen Brown
Journal:  Ethn Dis       Date:  2019-07-18       Impact factor: 1.847

3.  Neuropsychological care and rehabilitation of cancer patients with chemobrain: strategies for evaluation and intervention development.

Authors:  Pascal Jean-Pierre; Douglas Johnson-Greene; Thomas G Burish
Journal:  Support Care Cancer       Date:  2014-03-27       Impact factor: 3.603

Review 4.  Cognitive Impairment Associated with Cancer: A Brief Review.

Authors:  J Cara Pendergrass; Steven D Targum; John E Harrison
Journal:  Innov Clin Neurosci       Date:  2018-02-01

Review 5.  Plausible biochemical mechanisms of chemotherapy-induced cognitive impairment ("chemobrain"), a condition that significantly impairs the quality of life of many cancer survivors.

Authors:  Xiaojia Ren; Diana Boriero; Luksana Chaiswing; Subbarao Bondada; Daret K St Clair; D Allan Butterfield
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2019-02-10       Impact factor: 5.187

6.  Self-reported memory problems in adult-onset cancer survivors: effects of cardiovascular disease and insomnia.

Authors:  Pascal Jean-Pierre; Michael A Grandner; Sheila N Garland; Elizabeth Henry; Girardin Jean-Louis; Thomas G Burish
Journal:  Sleep Med       Date:  2015-03-18       Impact factor: 3.492

7.  It Is Not What You Think: Associations Between Perceived Cognitive and Physical Status and Prognostic Understanding in Patients With Advanced Cancer.

Authors:  Keiko Kurita; Eugenia L Siegler; M Cary Reid; Renee C Maciejewski; Holly G Prigerson
Journal:  J Pain Symptom Manage       Date:  2018-05-10       Impact factor: 3.612

8.  Survivorship: cognitive function, version 1.2014.

Authors:  Crystal S Denlinger; Jennifer A Ligibel; Madhuri Are; K Scott Baker; Wendy Demark-Wahnefried; Debra L Friedman; Mindy Goldman; Lee Jones; Allison King; Grace H Ku; Elizabeth Kvale; Terry S Langbaum; Kristin Leonardi-Warren; Mary S McCabe; Michelle Melisko; Jose G Montoya; Kathi Mooney; Mary Ann Morgan; Javid J Moslehi; Tracey O'Connor; Linda Overholser; Electra D Paskett; Muhammad Raza; Karen L Syrjala; Susan G Urba; Mark T Wakabayashi; Phyllis Zee; Nicole R McMillian; Deborah A Freedman-Cass
Journal:  J Natl Compr Canc Netw       Date:  2014-07       Impact factor: 11.908

9.  Cognitive problems among breast cancer survivors: loneliness enhances risk.

Authors:  Lisa M Jaremka; Juan Peng; Robert Bornstein; Catherine M Alfano; Rebecca R Andridge; Stephen P Povoski; Adele M Lipari; Doreen M Agnese; William B Farrar; Lisa D Yee; William E Carson; Janice K Kiecolt-Glaser
Journal:  Psychooncology       Date:  2014-04-11       Impact factor: 3.894

10.  Goal disturbance in early-stage breast cancer survivors.

Authors:  Marcie D Haydon; Annette L Stanton; Patricia A Ganz; Julienne E Bower
Journal:  J Psychosoc Oncol       Date:  2019-01-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.